HEAT

• HEAT (Helicobacter Eradication Aspirin Trial) is a large simple double-blind placebo controlled outcomes study of Helicobacter pylori (H. pylori) eradication to prevent ulcer bleeding in aspirin users. It will be run by the University of Nottingham, with recruiting centres across the UK. This trial is funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) Programme.

• There are 1,340 practices across the UK participating in this trial with 30,000 enrolled patients.

  
  
  
  
  
  
  
  
  
  
  

ATTACK

• ATTACK (Aspirin To Target Arterial Events In Chronic Kidney Disease). This new clinical trial will be starting in August 2018 and will investigate the use of aspirin to reduce stroke and heart attacks in patients with established CKD